Suspected serotonin syndrome in a patient being treated with methylene blue for ifosfamide encephalopathy

Journal of Oncology Pharmacy Practice

Volumn 18, Issue 4, 2012, Pages 436-439

  McDonnell, A M ^a   Rybak, I ^a   Wadleigh, M ^b   Fisher, D C ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

ifosfamide encephalopathy; Methylene blue; serotonin syndrome

Indexed keywords

AMFEBUTAMONE; APREPITANT; CARBOPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; METHYLENE BLUE; MONOAMINE OXIDASE INHIBITOR; PAROXETINE; PREDNISONE; VINCRISTINE;

ADD ON THERAPY; AGED; ARTICLE; BRAIN DISEASE; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DRUG INDICATION; DRUG POTENCY; ELECTRON THERAPY; FEMALE; FOOD AND DRUG ADMINISTRATION; HUMAN; IFOSFAMIDE INDUCED ENCEPHALOPATHY; INTENSIVE CARE UNIT; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; SEROTONIN SYNDROME; TACHYPNEA;

BRAIN DISEASES; HUMANS; IFOSFAMIDE; METHYLENE BLUE; SEROTONIN SYNDROME;

EID: 84869050475     PISSN: 10781552     EISSN: 1477092X     Source Type: Journal    
DOI: 10.1177/1078155211433231     Document Type: Article

References (26)

1. American Regent, Inc (Rev 2011). 'Methylene blue for injection, USP 1%', Package Insert, http://www.americanregent.com/documents/ Product36PrescribingInformation.pdf (2011, accessed 10 October 2011).
2. Zulian GB, Tullen E, Maton B. Methylene blue for ifosfamide-associated encephalopathy. N Engl J Med. 1995 ; 332: 1239-1240
3. Giovanis P, Garna A, Marcante M, Nardi K, Giusto M. Ifosfamide encephalopathy and use of methylene blue. A case report of different sequential neurotoxicity. Tumori. 2009 ; 95: 545-546
4. Patel PN. Methylene blue for management of ifosfamide-induced encephalopathy. Ann Pharmacother. 2006 ; 40: 299-303
5. Pelgrims J, De Vos F, Van den Brande J, Schrijvers D, Prove A, Vermorken JB. Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature. Br J Cancer. 2000 ; 82 (2). 291-294
6. Ajithkumar T, Parkinson C, Shamshad F, Murray P. Ifosfamide encephalopathy. Clin Oncol. 2007 ; 19: 108-114
7. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005 ; 352: 1112-1120
8. Ramsay RR, Dunford C, Gillman PK. Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction. Br J Pharmacol. 2007 ; 152: 946-951
9. Dunkley EJC, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter serotonin toxicity criteria: simple and accurate diagnostic decision rules for serotonin toxicity. Q J Med. 2003 ; 96: 635-642
10. Sweet G, Standiford SB. Methylene blue-associated encephalopathy. J Am Coll Surg. 2007 ; 204: 454-458
11. Kartha SS, Chacko CE, Bumpous JM, Fleming M, Lentsch EJ, Flynn MB. Toxic metabolic encephalopathy after parathyroidectomy with methylen blue localization. Otolaryngol Head Neck Surg. 2006 ; 135: 765-768
12. Ng KW, Cameron AJD, Liang R, Rahman H. Serotonin syndrome following methylene blue infusion during parathyroidectomy: a case report and literature review. Can J Anesth. 2008 ; 55: 36-41
13. Ng KW, Cameron AJD. The role of methylene blue in serotonin syndrome: a systemic review. Psychosomatics. 2010 ; 51: 194-200
14. Martindale SJ, Stedeford JC. Neurological sequelae following methylene blue injection for parathyroidectomy. Anaesthesia. 2003 ; 58: 1041-1042
15. Bach KK, Lindsay FW, Berg LS, Howard RS. Prolonged postoperative disorientation after methylene blue infusion during parathyroidectomy. Anesth Analg. 2004 ; 99: 1573-1574
16. Majithia A, Stearns MP. Methylene blue toxicity following infusion to localize parathyroid adenoma. J Laryngol Otol. 2006 ; 120: 138-140
17. Mathew S, Linhartova L, Raghuraman G. Hyperpyrexia and prolonged postoperative disorientation following methylene blue infusion during parathyroidectomy. Anaesthesia. 2006 ; 61: 580-583
18. Mihai R, Mitchell EW, Warwick J. Dose-response and postoperative confusion following methylene blue infusion during parathyroidectomy. Can J Anesth. 2007 ; 54: 79-81
19. Khan MA, North AP, Chadwick DR. Prolonged postoperative altered mental status after methylene blue infusion during parathyroidectomy: a case report and review of the literature. Ann R Coll Surg Engl. 2007 ; 89: 9-11
20. Shanmugam G, Kent B, Alsaiwadi T, Baskett R. Serotonin syndrome following cardiac surgery. Interact Cardiovasc Thorac Surg. 2008 ; 7: 656-658
21. Khavandi A, Whitaker J, Gonna H. Serotonin toxicity precipitated by concomitant use of citalopram and methylene blue. Med J Aust. 2008 ; 9: 534-535
22. Schwiebert C, Irving C, Gillman PK. Small doses of methylene blue, previously considered safe, can precipitate serotonin toxicity. Anaesthesia. 2009 ; 64: 924-924
23. Heritier Barras AC, Walder B, Seeck M. Serotonin syndrome following methylene blue infusion: a rare complication of antidepressant therapy. J Neurol Neurosurg Psychiat. 2010 ; 81 (12). 1412-1413
24. Pollack G, Pollack A, Delfiner J, Fernandez J. Parathyroid surgery and methylene blue: a review with guidelines for safe intraoperative use. Laryngoscope. 2009 ; 119: 1941-1946
25. Rowley M, Riutort K, Shapiro D, Casler J, Festic E, Freeman WD. Methylene blue-associated serotonin syndrome: a green encephalopathy after parathyroidectomy. Neurocrit Care. 2000 ; 11: 88-93
26. Stanford SC, Standford BJ, Gillman PK. Risk of severe serotonin toxicity following co-administration of methylene blue and serotonin reuptake inhibitors: an update on a case report of post-operative delirium. J Psychopharmacol. 2010 ; 24 (10). 1433-1438